Sesen Bio enters into exclusive license agreement for Vicineum™ in Greater China with Qilu Pharmaceutical

Torreya advised Sesen Bio on the licensing transaction

Cambridge, MA and Jinan, China, August 3, 2020

Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, entered into an exclusive regional license agreement for Vicineum™ in China, Hong Kong, Macau and Taiwan (the “Territory”) with Qilu Pharmaceutical. Vicineum is currently in the follow-up stage of a Phase 3 registration trial for the treatment of high-risk, BCG-unresponsive NMIBC.

According to the terms of the agreement, Sesen Bio will receive an upfront payment of US$12 million and is eligible to receive up to US$23 million in additional technology transfer and regulatory milestone payments. Upon successful commercialization in the Territory, Sesen Bio will receive royalties on net sales in the Territory as well.

The partnership with Qilu provides Sesen with support for the expansion of their development efforts and helps strengthen Sesen's balance sheet as it prepares for the commercialization of Vicineum in the USA. The agreement also outlines terms to transfer the Vicineum manufacturing technology to Qilu Pharmaceutical, whose world-class manufacturing expertise will allow for increased production to meet the anticipated rising global demand in NMIBC.

Torreya advised Sesen Bio on this transaction, which was completed entirely virtually, which highlights Torreya’s ability to get cross-border deals done during the COVID-19 pandemic. This transaction reinforces Torreya’s strength and leadership position in China. Torreya has completed 12 transactions involving a China party since 2018. Due to its dedicated China licensing advisory team and market knowledge, Torreya has rapidly become the most active advisory firm in China licensing in the Life Sciences sector.

ABOUT SESEN BIO:
For more information about Sesen Bio, please see: www.sesenbio.com

ABOUT QILU PHARMACEUTICAL:
For more information about Qilu, please see: www.qilu-pharma.com

Sesen Bio’s Press Release
Qilu Pharmaceutical’s Press Release

Torreya Contact

JIE LIU
Managing Director | New York Office
jie.liu@torreya.com | 917.683.4003 | torreya.com

Torreya is a global advisory firm serving the life sciences industry. Please visit torreya.com for more information. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. Torreya Partners LLC is a Delaware Limited Liability Company while Torreya Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 150 Aldersgate Street, London EC1A 4AB. Torreya Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torreya Capital and its representatives do not provide tax or legal advice and each tax and financial situation is unique. Investors should consult their tax and/or legal advisor for advice and information concerning their particular situation.